|Bid||82.61 x 800|
|Ask||84.03 x 1000|
|Day's Range||83.33 - 86.62|
|52 Week Range||72.67 - 141.86|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||7.85|
|Earnings Date||Apr 22, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||141.05|
Alexion Pharmaceuticals (ALXN) closed at $86.14 in the latest trading session, marking a +1.98% move from the prior day.
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...
Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $82.50, moving +0.17% from the previous trading session.
Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Some of the largest health care stocks in the world include Johnson & Johnson (JNJ) and Pfizer, Inc. (PFE).
Coronavirus is probably the 1 concern in investors’ minds right now. It should be. On February 27th we published this article and predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 months. We also told you to short the market ETFs and buy long-term […]
Alexion Pharmaceuticals, Inc. today announced that nine abstracts have been accepted for presentation at AAN.
Take a look at biopharma, Bank of America analyst Geoff Meacham argues in a new note out Thursday. “Despite market volatility from [coronavirus], we expect limited impact on biopharma fundamentals,” Meacham wrote. Meacham played down the excitement over possible treatments and vaccines for Covid-19, saying that they remain months, or even a year, away.
This self-described "lone ranger" may not be far off with his clinical trial plan as new coronavirus cases increase globally.
Despite having revenue from two commercial products, Alnylam Pharmaceuticals lost $886 million in 2019 — its biggest-ever net loss. But CEO John Maraganore believes the biotech could soon be one of the top five biopharma companies in the country.
While women make up one-quarter of leadership teams among the 25 largest publicly traded companies in Massachusetts, they represent just 4 percent of CEOs, according to a new report.
Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company that researches and manufactures treatments of severe and rare health disorders; I consider this an undervalued growth stock, notes Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Last week, you might have seen that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its full-year result to the...
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.
Alexion Pharmaceuticals topped Wall Street's fourth-quarter revenue and adjusted earnings expectations early Thursday, but Alexion Pharma stock slipped on mixed guidance for 2020.